Patents Examined by Scott Long
  • Cereblon-based heterodimerizable chimeric antigen receptors
    Patent number: 11331380
    Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods thereof.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 17, 2022
    Assignee: CELGENE CORPORATION
    Inventor: Shuichan Xu
  • PD-1 CAR NK-92 cell and preparation method and use thereof
    Patent number: 11331345
    Abstract: Provided are a PD-1 CAR NK-92 cell and a preparation method and use thereof. The PD-1 CAR NK-92 cell expresses PD-1-CD8™-4-1BB-CD3? fusion protein in NK-92 cells. The PD-1 CAR NK-92 is obtained by infecting an NK92 cell line with a PD-1 CAR molecule and obtaining monoclonal cells by means of flow screening, and culturing and expanding CAR NK92 monoclonal cell strains with stable traits and a high killing activity. The cells can be produced on a large scale, can be used in different patients without GVHR rejection, and have a specific killing activity and significant therapeutic effect on tumors.
    Type: Grant
    Filed: April 21, 2019
    Date of Patent: May 17, 2022
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventors: Huashun Li, Baolei Wang, Kunkun Han, Baoyong Ren
  • Methods and compositions for producing hepatocyte-like cells
    Patent number: 11291691
    Abstract: Methods are provided for producing a population of hepatocyte-like cells (iHeps) from a population of adipocyte-derived stem cells (ASCs). Aspects of the methods include placing a population of ASCs into a three dimensional culture (e.g., hanging drop suspension culture, high density culture, spinner flask culture, microcarrier culture, etc.), and contacting the cells with a first and second culture medium. Also provided are methods of treating an individual, which include producing a population of iHeps from a population of ASCs, and administering an effective number of iHeps into the individual. Kits for practicing the methods are also described herein.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: April 5, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gary Peltz, Dan Xu
  • Targeted disruption of the MHC cell receptor
    Patent number: 11285175
    Abstract: Disclosed herein are methods and compositions for inactivating MEW genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gary K. Lee, David Paschon, Lei Zhang
  • Synthetic nanostructures including nucleic acids and/or other entities
    Patent number: 11285106
    Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 29, 2022
    Assignee: Northwestern University
    Inventors: C. Shad Thaxton, Chad A. Mirkin, Kaylin M. McMahon, Sushant Tripathy, Raja Kannan Mutharasan, David M. Leander, Andrea Luthi
  • Mycological biopolymers grown in void space tooling
    Patent number: 11277979
    Abstract: A mycological biopolymer product consisting entirely of fungal mycelium is made by inoculating a nutritive substrate with a selected fungus in a sealed environment except for a void space, which space is subsequently filled with a network of undifferentiated fungal mycelium. The environmental conditions for producing the mycological biopolymer product, i.e. a high carbon dioxide (CO2) content (from 5% to 7% by volume) and an elevated temperature (from 85° F. to 95° F.), prevent full differentiation of the fungus into a mushroom. There are no stipe, cap, or spores produced. The biopolymer product grows into the void space of the tool, filling the space with an undifferentiated mycelium chitin-polymer, which is subsequently extracted from the substrate and dried.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: March 22, 2022
    Assignee: Ecovative Design LLC
    Inventors: Lucy Greetham, Gavin R. McIntyre, Eben Bayer, Jacob Winiski, Sarah Araldi
  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 11268077
    Abstract: Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF).
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: March 8, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Bibhu Prasad Mishra
  • Functional prediction of cellular functions by means of microRNA expression profiling in mesenchymal stem cells
    Patent number: 11266687
    Abstract: Non-coding RNA, such as miRNA, expression data derived from a cell population is used to infer the propensity of that cell population for a cellular functional effect for a pre-determined purpose, which effect is temporally, procedurally or interventionally separated from the cell population from which the expression data is derived. Thereby, the cellular functional effect of a cell population can be predicted in order to improve decisions and selections to be made relating to the use of cells, e.g. from cells deriving from different donors or batches, for use in bioprocess application or cell therapeutics, in order to enhance productivity, efficiency and/or efficacy.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 8, 2022
    Assignee: SISTEMIC SCOTLAND LTD
    Inventors: David Mallinson, Donald Dunbar, Elaine Gourlay, Daria Olijnyk, James Reid
  • Methods related to minimally polarized functional units
    Patent number: 11266765
    Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 8, 2022
    Assignee: PolarityTE, Inc.
    Inventor: Denver M. Lough
  • Methods for targeted insertion of DNA in genes
    Patent number: 11254930
    Abstract: Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: February 22, 2022
    Assignee: BLUEALLELE CORPORATION
    Inventor: Nicholas J. Baltes
  • Cartilage regenerative material
    Patent number: 11241518
    Abstract: An object of the invention is to provide a cartilage regenerative material that is capable of regenerating bone and cartilage using cells. Provided is a cartilage regenerative material including a cell construct, which includes biocompatible polymer blocks and stem cells, in which a plurality of the biocompatible polymer blocks are disposed in gaps between a plurality of the stem cells.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: February 8, 2022
    Assignees: FUJIFILM Corporation, JAPAN TISSUE ENGINEERING CO., LTD.
    Inventors: Kentaro Nakamura, Hayato Miyoshi, Satoko Hada, Masatoki Watanabe
  • Methods of treating disease by metabolic control of T-cell differentiation
    Patent number: 11241455
    Abstract: Provided herein are methods for treating an individual for a disease (e.g., an autoimmune disease or a cancer) using an active agent which affects metabolism of ?-ketoglutarate (?-KG) and/or 2-hydroxyglutarate (2-HG) in differentiating T cells. In some embodiments, a Got1 inhibitor is used to generate a population of T cells enriched in peripheral regulatory T (iTreg) cells, which population enriched in iTreg cells may find use in treating an autoimmune disease. In some embodiments, a TCA cycle-associated metabolite, or a derivative thereof, is used to generate a population of T cells in enriched in IL-17- and IL-17F-producing CD4 T (TH17) cells, which population enriched in TH17 cells may find use in treating a cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 8, 2022
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Tao Xu, Sheng Ding
  • Isolation of stem cells from adipose tissue by ultrasonic cavitation, and methods of use
    Patent number: 11236324
    Abstract: In one embodiment, the present invention relates to a non-enzymatic method for isolating stem cells from adipose tissue, wherein the method comprises treating adipose tissue with ultrasonic cavitation to break up the adipose tissue and lyses mature adipocytes, resulting in a stromal vascular fraction containing viable stromal/stem cells.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: February 1, 2022
    Assignee: Cell-Innovations IP Pty Ltd
    Inventors: Ralph Bright, Pelin Bright, Bruce Hansen, Wayne Thomas
  • Genetically modified cells, tissues, and organs for treating disease
    Patent number: 11234418
    Abstract: Genetically modified cells, tissues, and organs for treating or preventing diseases are disclosed. Also disclosed are methods of making the genetically modified cells and non-human animals.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: February 1, 2022
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Bernhard J. Hering, Christopher Burlak
  • Maximizing T-cell memory and compositions and methods therefor
    Patent number: 11229668
    Abstract: Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 25, 2022
    Assignees: NantCell, Inc., Nant Holdings IP, LLC
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Patrick Soon-Shiong, Hing Wong, Wenxin Xu
  • Cell repopulated collagen matrix for soft tissue repair and regeneration
    Patent number: 11229725
    Abstract: The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: January 25, 2022
    Assignee: ALLOSOURCE
    Inventors: Reginald L. Stilwell, Brent Atkinson, Yaling Shi, Brian Dittman
  • Modulatable switch for selection of donor modified cells
    Patent number: 11213548
    Abstract: The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: January 4, 2022
    Assignees: CSL Behring Gene Therapy, Inc., CSL Gene Therapy Pty Ltd.
    Inventors: Christopher Walter Alma, Jeffrey Bartlett, Louis Randall Breton, Geoffrey Phillip Symonds, Ming Yan
  • Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
    Patent number: 11213594
    Abstract: Disclosed are compositions for delivering gene editing molecules to a cell. Exemplary compositions comprise a micelle assembled from a plurality of triblock copolymers, wherein each triblock copolymer having at least one hydrophobic block, at least one hydrophilic block, and at least one poly(L-histidine) block, wherein: the at least one poly(L-histidine) block complexes with the at least one gene editing molecule; and the at least one poly(L-histidine) block is capable of a pH dependent release of the at least one gene editing molecule.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: January 4, 2022
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Paiman Peter Ghoroghchian, Gabriela Romero Uribe, Eric Ostertag
  • Artificial cells
    Patent number: 11207687
    Abstract: The invention relates to an artificial cell system comprising at least one droplet-interface bilayer (DIB) encased within a shell; a suspension comprising same; and a method and a device for the manufacture of same.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD
    Inventors: Oliver Castell, David Barrow, Divesh Baxani
  • Processing and use of reproductive tract fluids to improve the in vitro production of mammalian embryos
    Patent number: 11208622
    Abstract: Processing and use of fluids from the reproductive tract (biofluids) to improve the in vitro production of mammalian embryos comprising the following steps: a) fractionation and processing of biofluids through a sorting, purification, lyophilization and subsequent storage; b) a method of sperm capacitation in a culture medium supplemented with biofluids; c) in vitro fertilization in a medium enriched with biofluids and d) subsequent in vitro culture with development of the obtained embryos to any stage of preimplantational development in culture media supplemented with biofluids.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 28, 2021
    Assignee: UNIVERSIDAD DE MURCIA
    Inventors: Raquel Romar Andres, Maria Pilar Coy Fuster